



~~18~~
15.

Attorney's Docket No. 5218-39C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.
Serial No.: 09/525,808
Filed: March 15, 2000
For: *METHOD OF TREATING ENDOTHELIAL INJURY*

Confirmation No. 9764
Group Art Unit: 1642
Examiner: Christopher H. Yaen

August 29, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP. This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

The Commissioner is authorized to charge the \$180.00 fee specified in 37 C.F.R. § 1.17(p), to charge any deficiency or credit any overpayment, to Deposit Account 50-0220.

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Certificate of Mailing under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 29, 2003.

Sloan Smith Date of Signature: 08/29/03

09/03/2003 SZEWDIE1 00000040 500220 09525808

01 FC:1806 180.00 DA

SEP 02 2002

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Sheet	1	of	1
-------	---	----	---

Application Number	09/525,808
Filing Date	03/15/2000
First Named Inventor	Anagnostou
Group Art Unit	1642
Examiner Name	C.H. Yaen
Attorney Docket Number	5218-39C

[illegible][illegible]

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	2	Communication with Supplementary European Search Report, EP 97 94 0974, July 15, 2002	
	3	Bukowski et al., <i>Phase IV evaluation of clinical outcomes of PROCRIT (Epoetin alfa) in anemic cancer patients receiving chemotherapy</i> , Blood, Journal of the American Society of Hematology, Vol. 84, No. 10, Supp. 1, December 1994, p. 129A	
	4	Taylor et al., <i>Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin</i> , Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis, Vol. 6, No. 2, April 1995, pp. 100-104	
	5	Taylor et al., <i>Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients</i> , Kidney International, Vol. 44, No. 1, July 1993, pp. 182-190	
	6	Reinhart, <i>Shear-dependence of endothelial functions</i> , Experientia, Vol. 50, No. 2, February 15, 1994, pp. 87-93	
	7	U.S. Patent Application Serial No. 09/525,797 filed March 15, 2000	

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.